Xylazine in Forensic Toxicology: Detection, Metabolites, and Interpretation

Direct answer: Xylazine is a non-opioid alpha-2 adrenergic agonist used in veterinary medicine that now appears in the illicit drug supply, frequently with fentanyl. In forensic toxicology, a xylazine result can establish analytical detection when the method is fit for purpose, but the concentration should not be treated as a stand-alone clock for time of use, a universal measure of impairment, or proof that xylazine alone caused death.

Why xylazine matters in forensic toxicology

Xylazine has become an important target in death investigation, impaired-driving, clinical, and drug-surveillance work because exposure may occur without the user knowing it is present. The CDC describes xylazine as a non-opioid sedative that is increasingly found in the U.S. illegal drug supply and linked to overdose deaths, especially in combination with opioids such as fentanyl. Xylazine can produce sedation, bradycardia, hypotension, and respiratory depression, while naloxone does not reverse xylazine itself. In mixed-drug cases, however, naloxone remains appropriate when an opioid exposure is suspected because it can reverse the opioid component.

For current drug-supply context, compare the site’s Emerging Drug Toxicology 2026 overview and its separate discussion of medetomidine, another alpha-2 agonist increasingly encountered with illicit fentanyl. For analyte-by-analyte differences in targets, metabolites, screening gaps, and interpretation, see Medetomidine vs Xylazine in Forensic Toxicology.

What specimens can be tested for xylazine?

Xylazine can be measured in blood and urine, and forensic laboratories may include it in broader LC-MS/MS panels. The specimen matters. Blood is generally more useful when the question concerns circulating drug at or near a relevant event, while urine is principally an exposure matrix and can extend detection because parent drug and metabolites may persist after blood concentrations fall.

A 2024 Journal of Analytical Toxicology method validated LC-MS/MS analysis of more than 250 novel synthetic opioids plus xylazine in blood and urine, illustrating how modern targeted panels can incorporate xylazine alongside fentanyl-related compounds. A separate 2024 Journal of Chromatography B method validated quantitative LC-MS/MS analysis of xylazine, fentanyl, norfentanyl, 4-ANPP, acetyl fentanyl, and fluorofentanyl-related compounds in postmortem blood.

What does a negative routine toxicology screen mean?

A negative routine screen does not necessarily exclude xylazine exposure. Whether xylazine could have been detected depends on the laboratory’s scope, analytical platform, reporting rules, cutoff or limit of detection, specimen type, and timing. Some routine immunoassay panels are drug-class based and do not target xylazine. A case review should therefore identify the actual analyte list and method rather than assuming that a generic “toxicology screen” included xylazine.

This is the same analytical principle that applies to other emerging substances: absence from a report may reflect absence from the method rather than proven absence from the specimen.

Xylazine metabolites can expand the evidence of exposure

Human metabolism data are developing. Recent work has characterized xylazine and major urinary metabolites in people exposed to fentanyl/xylazine mixtures. Measuring metabolites can be important because a metabolite may remain detectable after the parent compound has declined, but metabolite patterns should not be converted into a precise time-since-use estimate without validated human pharmacokinetic support for that inference.

A 2026 Analytical Biochemistry paper described a validated quantitative LC-MS/MS urine method for xylazine and emphasized a practical problem for current testing: xylazine is not included in many routine toxicology screens. That study reported a validated dilute-and-shoot method designed for high-throughput clinical toxicology and surveillance.

Can a xylazine blood concentration prove impairment?

Not by itself. A numerical concentration must be interpreted in context. Important variables include specimen type and collection time, co-occurring drugs, tolerance, medical treatment, analytical uncertainty, and the pharmacodynamic question being asked. The fact that xylazine is a sedative does not create a universally valid concentration-to-impairment threshold for forensic casework.

When fentanyl, benzodiazepines, alcohol, stimulants, or other central nervous system-active substances are also present, attributing observed behavior to one analyte requires additional evidence. The toxicology result should be integrated with scene information, witness observations, clinical records, driving evidence, autopsy findings, and the timing of specimen collection.

Postmortem xylazine interpretation

Postmortem interpretation requires particular restraint. A concentration measured after death is not automatically equivalent to the concentration at the time of a fatal event. Sampling site, postmortem interval, decomposition, redistribution, specimen integrity, and co-intoxicants can all affect interpretation. Peripheral and central blood should not be treated as interchangeable without evidence supporting that assumption for the analyte and case circumstances.

A 2025 forensic case report described fatal xylazine poisoning without other central nervous system drugs and quantified xylazine in blood by LC-MS/MS. That type of report can demonstrate that severe or fatal xylazine poisoning is possible, but a single case should not be converted into a universal lethal-concentration threshold.

For the specimen issue more generally, see Postmortem Blood Sampling Sites: Interpretation Guide.

New 2026 evidence: xylazine stability depends on matrix, concentration, temperature, and time

A September 18, 2026 Journal of Analytical Toxicology study from the Virginia Department of Forensic Science directly evaluated xylazine stability in preserved antemortem and postmortem blood. The authors tested 3 ng/mL and 160 ng/mL specimens at approximately 23 °C, 2–8 °C, and -20 °C and defined instability as a measured concentration deviating by more than ±20% from Day 0.

The results caution against assuming that refrigeration or freezing automatically preserves xylazine. At room temperature, xylazine was unstable by Day 7 at 3 ng/mL and by Day 10 at 160 ng/mL in both matrices. Refrigerated antemortem blood became unstable by Day 10 at 3 ng/mL and Day 24 at 160 ng/mL; refrigerated postmortem blood remained within the study criterion longer, becoming unstable by Day 29 at both concentrations. In the study’s -20 °C condition, instability also occurred, and the timing differed by concentration and by antemortem versus postmortem matrix.

For case review, storage history is therefore part of the analytical evidence. A defensible interpretation should identify the specimen matrix, preservative, initial concentration range, storage temperature, duration before analysis, freeze-thaw history, and the laboratory’s own validated stability data. A later measured concentration should not automatically be treated as the concentration that existed at collection merely because the sample was refrigerated or frozen.

Source: Riley-Carrier P, Wagner R. Xylazine: Evaluation of antemortem and postmortem specimen storage conditions. J Anal Toxicol. Published online September 18, 2026. doi:10.1093/jat/bkag081.

How xylazine differs from medetomidine

Xylazine and medetomidine are both alpha-2 adrenergic agonists, but they are not analytically or pharmacologically interchangeable. By 2026, CDC had separately warned about medetomidine in the illicit fentanyl supply and reported substantial growth in forensic laboratory detections. A laboratory method that includes xylazine does not necessarily include medetomidine, and vice versa. The analyte list should be verified directly from the laboratory method or scope.

Laboratory records worth reviewing

For an evidentiary review, the final report is only the starting point. Depending on the issue, useful records can include:

the laboratory’s validated xylazine method and analyte scope;
calibration model, calibrator concentrations, and acceptance criteria;
limits of detection and quantitation and any reporting cutoff;
internal-standard performance;
ion transitions, retention-time criteria, qualifier/quantifier criteria, and chromatograms;
quality-control results and batch acceptance records;
matrix-effect, recovery, interference, carryover, dilution-integrity, and stability data from validation;
specimen collection, storage, transport, and freeze-thaw history;
chain-of-custody and accession records;
the complete toxicology panel, including fentanyl, norfentanyl, other opioids, sedatives, stimulants, and ethanol where relevant.

Common interpretation errors

Assuming the routine panel included xylazine. Confirm the analyte scope.
Treating urine concentration as a measure of contemporaneous impairment. Urine primarily establishes exposure and excretion.
Using a single blood concentration as a precise time-of-use clock. Current human pharmacokinetic data do not support that shortcut in ordinary casework.
Ignoring co-intoxicants. Xylazine frequently appears in polysubstance cases, particularly with fentanyl.
Applying a concentration from one published fatality as a universal lethal threshold. Case reports are informative but not population reference ranges.
Equating analytical detection with causation. Detection, pharmacologic contribution, impairment, and cause of death are distinct questions.

Frequently asked questions

Is xylazine an opioid?

No. Xylazine is a non-opioid alpha-2 adrenergic agonist sedative. It is nevertheless frequently encountered with illicit fentanyl.

Does naloxone reverse xylazine?

No. Naloxone reverses opioid effects, not xylazine itself. Because xylazine exposures often involve fentanyl or another opioid, naloxone is still recommended for suspected opioid overdose while emergency care is obtained.

Can LC-MS/MS identify xylazine?

Yes. Validated LC-MS/MS methods have been published for blood and urine. The evidentiary question is not merely whether LC-MS/MS is capable of detecting xylazine, but whether the particular laboratory method was validated, properly controlled, and applied within its validated scope.

Can xylazine be missed by a routine tox screen?

Yes. A negative result does not exclude xylazine if the method did not target it or if concentration was below the method’s reporting capability.

Selected authoritative and peer-reviewed sources

Technical note: This page is intended as a forensic toxicology reference. Interpretation in a specific case requires review of the actual method, specimen history, case facts, and complete toxicology record.